Application of computational methods for anticancer drug discovery, design, and optimization
暂无分享,去创建一个
Diego Prada-Gracia | Sara Huerta-Yépez | Liliana M Moreno-Vargas | L. Moreno-Vargas | D. Prada-Gracia | S. Huerta-Yepez
[1] J J Baldwin,et al. Carbonic anhydrase inhibitors for the treatment of glaucoma , 2023, Медицинская этика.
[2] Xin Li,et al. Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach , 2012, BMC Systems Biology.
[3] S. Vasavanonda,et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[4] Sheng-Yong Yang,et al. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.
[5] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[6] Suwen Zhou,et al. Pharmacophore-Based 3D-QSAR Modeling, Virtual Screening and Molecular Docking Analysis for the Detection of MERTK Inhibitors with Novel Scaffold. , 2016, Combinatorial chemistry & high throughput screening.
[7] Joo Chuan Tong,et al. Recent advances in computer-aided drug design , 2009, Briefings Bioinform..
[8] L. Bourgon,et al. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. , 2005, Antiviral research.
[9] Catherine Jessica Lai,et al. Pharmacophore-based screening targeted at upregulated FN1, MMP-9, APP reveals therapeutic compounds for nasopharyngeal carcinoma , 2016, Comput. Biol. Medicine.
[10] J. Baselga,et al. ZD1839 (‘Iressa’)1,2 as an Anticancer Agent , 2012, Drugs.
[11] P. Imming,et al. Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.
[12] Yi-Wei Chang,et al. Structure–Activity Relationship Studies of 3‐Aroylindoles as Potent Antimitotic Agents , 2006, ChemMedChem.
[13] Graham J. Durant,et al. Proceedings: The pharmacology of cimetidine, a new histamine H2-receptor antagonist. , 1975 .
[14] Sean Ekins,et al. Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.
[15] Jian Yu,et al. BH3 mimetics to improve cancer therapy; mechanisms and examples. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[16] Norbert Bischofberger,et al. Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.
[17] D. M. Ryan,et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro , 1993, Antimicrobial Agents and Chemotherapy.
[18] Sanjay Goel,et al. Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase , 2003, Expert review of anticancer therapy.
[19] Roberto Todeschini,et al. Molecular descriptors for chemoinformatics , 2009 .
[20] Timothy P. Spicer,et al. In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632 , 2000, Antimicrobial Agents and Chemotherapy.
[21] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[22] M. Jarman,et al. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. , 1998, Journal of medicinal chemistry.
[23] J W Black,et al. The pharmacology of cimetidine, a new histamine H2-receptor antagonist. , 1975, British journal of pharmacology.
[24] D. Ho,et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.
[25] Mohane Selvaraj Coumar,et al. Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. , 2009, Journal of medicinal chemistry.
[26] W. Brass,et al. New Life Tables for Latin American Populations in the Nineteenth and Twentieth Centuries. , 1969 .
[27] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[28] C M Cook,et al. The three-dimensional x-ray crystal structure of HIV-1 protease complexed with a hydroxyethylene inhibitor. , 1991, Advances in experimental medicine and biology.
[29] B Rubin,et al. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. , 1977, Science.
[30] D W Cushman,et al. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. , 1977, Biochemistry.
[31] Marc Ladanyi,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.
[32] Vinita Mishra,et al. Ligand based virtual screening to find novel inhibitors against plant toxin Ricin by using the ZINC database , 2011, Bioinformation.
[33] Ming-Sound Tsao,et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.
[34] B. Bonavida,et al. Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies. , 2011, Critical reviews in oncogenesis.
[35] Brian K Shoichet,et al. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.
[36] A. Zarghi,et al. Design, Synthesis, and Biological Evaluation of New 2-Phenyl-4H-chromen-4-one Derivatives as Selective Cyclooxygenase-2 Inhibitors , 2014, Scientia pharmaceutica.
[37] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[38] W. Prince,et al. Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers , 2002, Journal of clinical pharmacology.
[39] S. Noha,et al. Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques , 2011, Bioorganic & medicinal chemistry letters.
[40] Irene T Weber,et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.
[41] A. Odermatt,et al. Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases , 2015, Molecules.
[42] C. Laggner,et al. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening , 2011, The Journal of Steroid Biochemistry and Molecular Biology.
[43] Massoud Amanlou,et al. Potent Human Telomerase Inhibitors: Molecular Dynamic Simulations, Multiple Pharmacophore-Based Virtual Screening, and Biochemical Assays , 2015, J. Chem. Inf. Model..
[44] M. Hatada,et al. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.
[45] W. L. Jorgensen. The Many Roles of Computation in Drug Discovery , 2004, Science.
[46] F A Quiocho,et al. The structure of carboxypepidase A. V. Studies of enzyme-substrate and enzyme-inhibitor complexes at 6 A resolution. , 1967, The Journal of biological chemistry.
[47] Devadasan Velmurugan,et al. Identification of novel natural inhibitor for NorM – a multidrug and toxic compound extrusion transporter – an insilico molecular modeling and simulation studies , 2017, Journal of biomolecular structure & dynamics.
[48] Peter J Piliero,et al. Atazanavir: a novel HIV-1 protease inhibitor , 2002, Expert opinion on investigational drugs.
[49] M. Ondetti,et al. Design of angiotensin converting enzyme inhibitors , 1999, Nature Medicine.
[50] N. Spector,et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 , 2004, Oncogene.
[51] Ivet Bahar,et al. Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. , 2011, Current topics in medicinal chemistry.
[52] Paul Workman,et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[53] Sherburne F. Cook,et al. New Life Tables for Latin American Populations in the Nineteenth and Twentieth Centuries , 1969 .
[54] L. Kuo,et al. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.
[55] J F Davies,et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.
[56] Ping-Chiang Lyu,et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.
[57] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir , 2011, PLoS Comput. Biol..
[58] Maurizio Recanatini,et al. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. , 2008, Bioorganic & medicinal chemistry.
[59] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.
[60] Honglin Li,et al. Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. , 2011, Journal of medicinal chemistry.
[61] Li‐Ping Sun,et al. Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. , 2016, European journal of medicinal chemistry.
[62] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[63] O. Rosenheim,et al. The Ring-system of sterols and bile acids. Part II , 1932 .
[64] Christian Drosten,et al. Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro , 2005, Journal of Virology.
[65] Gisbert Schneider,et al. Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.
[66] Vannajan Sanghiran Lee,et al. Estimation of Inhibitory Effect against Tyrosinase Activity through Homology Modeling and Molecular Docking , 2015, Enzyme research.
[67] M. Youle,et al. Clinical potential of a new HIV protease inhibitor. , 1995, Journal of the International Association of Physicians in AIDS Care.
[68] S Seeber,et al. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. , 2003, International journal of clinical pharmacology and therapeutics.
[69] J. Baselga,et al. ZD1839 ('Iressa') as an anticancer agent. , 2000, Drugs.
[70] Irene T. Weber,et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.
[71] O. ROSENHEIM,et al. The Ring System of Sterols and Bile Acids , 1932, Nature.
[72] Mary K Joseph,et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.
[73] Scott Myers,et al. Drug discovery—an operating model for a new era , 2001, Nature Biotechnology.
[74] Tim Eisen,et al. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[75] Dinesh Kumar,et al. Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database , 2010, Bioinformation.
[76] M Elliott,et al. Zanamivir: from drug design to the clinic. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[77] G. Klebe,et al. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. , 2002, Angewandte Chemie.
[78] M. Kris,et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[79] Xiaowu Chen,et al. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. , 2000, Current medicinal chemistry.
[80] J. Irwin,et al. Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.
[81] R. Sturdevant,et al. Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer. , 1975, The New England journal of medicine.
[82] Y. Martin,et al. Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.
[83] David A. Stock,et al. BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents , 2000, Antimicrobial Agents and Chemotherapy.
[84] Gary Box,et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.
[85] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[86] Wim G. J. Hol,et al. PROTEIN CRYSTALLOGRAPHY AND COMPUTER-GRAPHICS TOWARD RATIONAL DRUG DESIGN , 1986 .
[87] Jian Yu,et al. PUMA, a potent killer with or without p53 , 2008, Oncogene.
[88] J. McCauley,et al. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. , 1994, Antiviral research.
[89] Ming-Sound Tsao,et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. , 2002, Molecular cancer therapeutics.
[90] Jean-Louis Reymond,et al. Exploring the chemical space of known and unknown organic small molecules at www.gdb.unibe.ch. , 2011, Chimia.
[91] Dale J. Kempf,et al. ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease , 1998, Antimicrobial Agents and Chemotherapy.
[92] I Judson,et al. Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.
[93] D. Bojanic,et al. Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.
[94] L. Pustilnik,et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.
[95] Faizan Ahmad,et al. Design and synthesis of a novel class of carbonic anhydrase-IX inhibitor 1-(3-(phenyl/4-fluorophenyl)-7-imino-3H-[1,2,3]triazolo[4,5d]pyrimidin 6(7H)yl)urea. , 2016, Journal of molecular graphics & modelling.
[96] Andrew P Combs. Structure-based drug design of new leads for phosphatase research. , 2007, IDrugs : the investigational drugs journal.
[97] Alexander Wlodawer,et al. Rational approach to AIDS drug design through structural biology. , 2002, Annual review of medicine.
[98] Lester A. Mitscher,et al. Chapter 36 – Glossary of Terms Used in Medicinal Chemistry (IUPAC Recommendations 1997) , 1998 .
[99] Corwin Hansch,et al. Comprehensive medicinal chemistry : the rational design, mechanistic study & therapeutic application of chemical compounds , 1990 .
[100] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[101] Cheng Luo,et al. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. , 2010, Journal of Medicinal Chemistry.
[102] Irene T. Weber,et al. Amprenavir complexes with HIV‐1 protease and its drug‐resistant mutants altering hydrophobic clusters , 2010, The FEBS journal.
[103] Peter W Swaan,et al. Computational approaches to modeling drug transporters. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[104] G. Shapiro,et al. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. , 2010, Current opinion in investigational drugs.
[105] K. Vousden,et al. PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.
[106] Eduardo E. Arriaga,et al. New Life Tables for Latin American Populations in the Nineteenth and Twentieth Centuries , 1969 .